REGULATORY

MHLW Gives Fuel Priority to Drug Deliveries in Quake-Hit Kumamoto

August 4, 2026

Identification Pass for Priority Refueling
Identification Pass for Priority Refueling

Japan’s Ministry of Health, Labor and Welfare (MHLW) has introduced a priority fuel supply scheme for vehicles delivering pharmaceuticals and medical devices in areas affected by the Kumamoto earthquake.

The MHLW issued an administrative communication on July 31 after receiving reports that shortages of gasoline and diesel fuel were disrupting deliveries to medical institutions, pharmacies, and evacuation centers in the disaster zone. The ministry said the measure was rolled out in coordination with the Ministry of Economy, Trade and Industry (METI).

Under the scheme, eligible organizations, including the Federation of Japan Pharmaceutical Wholesalers Association (JPWA), must submit vehicle and route information to the MHLW in advance. Registered vehicles presenting the administrative communication and an official identification pass will receive priority refueling at designated service stations operated under METI’s emergency fuel supply network.

Related Article

REGULATORY

By Kohei Hori

A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…

By Hayate Horiguchi

A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…

By Tatsuya Otsuka

On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…

By Hayate Horiguchi

Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…

By Shunsuke Tani

Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…